Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Nov 16, 2022 8:00 am EST
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator Nov 9, 2022 7:02 am EST
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting Oct 24, 2022 7:00 am EDT
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference Sep 7, 2022 7:00 am EDT
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock Jul 29, 2022 5:27 pm EDT